Companies · Pharmaceuticals

Telesis Therapeutics, LLC

PHILADELPHIA · Pharmaceuticals

Diligence memoA one-page analyst read on Telesis Therapeutics, LLC — recommendation, valuation, rhythm, risks.
$615K
Total raised · real
1
Rounds
Latest step-up
Top 87%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Oct 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Telesis Therapeutics, LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.00× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era.
  • Within the normal band (100% of peer median) for its niche.
Dormant
  • Last raise 4.7 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Telesis Therapeutics, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
4.7 yr record
Peak capital year was 2021 with $615K across 1 filings.
Market position
ahead of 14% of Pharmaceuticals peers
Capital scale is ahead of 14% of Pharmaceuticals peers; modeled value is above 22% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2021: $615K across 1 filings.
  • Largest single filing was $615K on 2021-10-28.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Telesis Therapeutics, LLC is one of 1613 Pharmaceuticals companies tracked from PHILADELPHIA. By capital raised it ranks in the long tail (ahead of 14% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
10
Investors (latest)
2021-10-28
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MPre-Seed · 2021-10-28 Raised $615K (real) Modeled valuation $13M (est)$615K$13MPre-Seed2021

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$615K · 2021

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$13.4M
Base estimate est.
$344K
Conservative case
$101.5M
Upside case
$3.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
4.7 yr
Elapsed time used
4.7 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
4.7 yr
On record since
2021
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$615K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.5× above median
This company$615K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$13.4M
Sector median$76.1M

Raised more than 14% of sector peers (real $). Modeled value above 22% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #23 of 46.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Elion Oncology, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Cyclone Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)Sonnet Biotherapeutics, Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Fastball Capital Group, Llc · Pre-Seed Raised $750K · modeled $35.5M (est)TamRx, LLC · Pre-Seed Raised $700K · modeled $33.1M (est)Veana Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $32.9M (est)Ariz Precision Medicine, Inc. · Pre-Seed Raised $685K · modeled $32.4M (est)Vascarta Inc. · Pre-Seed Raised $649K · modeled $28.1M (est)Enfuego Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $27.0M (est)Sincerus Pharmaceuticals Inc · Pre-Seed Raised $506K · modeled $23.9M (est)Neurodon Corp · Pre-Seed Raised $500K · modeled $23.7M (est)Elite Pharmaceuticals Inc /Nv/ · Pre-Seed Raised $3.3M · modeled $23.4M (est)Telesis Therapeutics, LLC (this company) Raised $615K · modeled $13.4M (est)Telesis Therapeutics, LLC
CompanyStageRaised · realValue · estvs peer med.
Elion Oncology, Inc.Pre-Seed$1.0M$47.3M3.54×
Cyclone Therapeutics, Inc.Pre-Seed$800K$37.8M2.83×
Sonnet Biotherapeutics, Inc.Pre-Seed$750K$35.5M2.66×
Fastball Capital Group, LlcPre-Seed$750K$35.5M2.66×
TamRx, LLCPre-Seed$700K$33.1M2.48×
Veana Therapeutics, Inc.Pre-Seed$1.4M$32.9M2.46×
Ariz Precision Medicine, Inc.Pre-Seed$685K$32.4M2.43×
Vascarta Inc.Pre-Seed$649K$28.1M2.10×
Enfuego Therapeutics, Inc.Pre-Seed$1.0M$27.0M2.02×
Sincerus Pharmaceuticals IncPre-Seed$506K$23.9M1.79×
Neurodon CorpPre-Seed$500K$23.7M1.77×
Elite Pharmaceuticals Inc /Nv/Pre-Seed$3.3M$23.4M1.75×
Telesis Therapeutics, LLC this companyPre-Seed$615K$13.4M1.00×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$615K2021-10-28$3.4M$13.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$615K2021-10-28
    • First recorded raise — entered as Pre-Seed.
    • 10 investors on this round.
Intelligence
Modeled next raise
$984K
Modeled next size est.range $640K$1.6M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Maurice T. Hampton2021-10
Registry & provenance

Telesis Therapeutics, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1827330
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
TF Tech Ventures, Inc.PharmaceuticalsPre-Seed$625K$8.3Msame sector · same stage
Goodsprout Co LLCPharmaceuticalsPre-Seed$600K$12.1Msame sector · same stage
Renavance Pharma, Inc.PharmaceuticalsPre-Seed$600K$4.7Msame sector · same stage
Lavior IncPharmaceuticalsPre-Seed$580K$13.3Msame sector · same stage
Gelesis Holdings, Inc.PharmaceuticalsPre-Seed$576K$7.9Msame sector · same stage
Pradama IncPharmaceuticalsPre-Seed$550K$14.2Msame sector · same stage
Oxygen Therapy, Inc.PharmaceuticalsPre-Seed$540K$14.2Msame sector · same stage
Trigemina IncPharmaceuticalsPre-Seed$705K$18.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Telesis Bio Inc.Biotech / PharmaSeries B$308.2M87%
Telo Therapeutics, Inc.BiotechnologySeries A$108.3M87%
Telomir Pharmaceuticals, Inc.PharmaceuticalsPre-Seed$9.7M82%
Gelesis Holdings, Inc.PharmaceuticalsPre-Seed$7.9M80%
Tempest Therapeutics, Inc.BiotechnologySeries C$307.4M79%
Synnovation Therapeutics, Inc.BiotechnologySeries B$136.3M79%
TP Therapeutics, Inc.PharmaceuticalsSeries C$2.8B79%
Virion Therapeutics, LLCBiotechnologySeries A$205.0M79%
Frequently asked
How much funding has Telesis Therapeutics, LLC raised?
Telesis Therapeutics, LLC has raised approximately $615K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Telesis Therapeutics, LLC's estimated valuation?
Provath's modeled valuation for Telesis Therapeutics, LLC is approximately $13.4M (modeled range $344K–$101.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Telesis Therapeutics, LLC at?
Telesis Therapeutics, LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Oct 28.
What does Telesis Therapeutics, LLC do and where is it based?
Telesis Therapeutics, LLC operates in the Pharmaceuticals sector, based in PHILADELPHIA.
Explore related

See where Telesis Therapeutics, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Telesis Therapeutics, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.